Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $48,000.

  • Biodesix's Capital Expenditures fell 79.22% to $48,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 81.17%. This contributed to the annual value of $3.2 million for FY2024, which is 85.91% down from last year.
  • Biodesix's Capital Expenditures amounted to $48,000 in Q3 2025, which was down 5.88% from $51,000 recorded in Q2 2025.
  • Biodesix's Capital Expenditures' 5-year high stood at $7.7 million during Q1 2023, with a 5-year trough of $48,000 in Q3 2025.
  • For the 3-year period, Biodesix's Capital Expenditures averaged around $2.4 million, with its median value being $839,000 (2024).
  • Per our database at Business Quant, Biodesix's Capital Expenditures spiked by 2,829.77% in 2023 and then tumbled by 97.35% in 2025.
  • Over the past 5 years, Biodesix's Capital Expenditures (Quarterly) stood at $530,000 in 2021, then soared by 264.15% to $1.9 million in 2022, then soared by 54.61% to $3.0 million in 2023, then tumbled by 71.88% to $839,000 in 2024, then plummeted by 79.22% to $48,000 in 2025.
  • Its last three reported values are $48,000 in Q3 2025, $51,000 for Q2 2025, and $74,000 during Q1 2025.